drugset / Trial / NCT05979051
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
Timeline
- Start
- 2023-11-16
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mepolizumab | Monoclonal antibody | — | Subcutaneous |
| Subject | SHR-1703 | Monoclonal antibody | — | Subcutaneous |